Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NT5C2 | P49902 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28900810 | 0.83 | BRD4 (0.62) | BRD4LMNASMN1; SMN2HSD17B10NT5C2 | |
| SCHEMBL18941373 | 0.82 | LMNA (0.33) | BRD4LMNA | |
| SCHEMBL5860314 | 0.79 | POLB (0.45) | BRD4LMNASMN1; SMN2HSD17B10CYP3A4 | |
| SCHEMBL7264355 | 0.78 | BRD4 (0.67) | BRD4NT5C2NT5ECREBBPTOP2A | |
| SCHEMBL17260474 | 0.76 | MAPT (0.34) | LMNAGAACYP3A4 | |
| SCHEMBL17260458 | 0.74 | SYK (0.47) | BRD4SMN1; SMN2HSD17B10CREBBPBRAF | |
| SCHEMBL28478879 | 0.74 | GDA (0.57) | SLC2A1 | |
| SCHEMBL28900808 | 0.72 | BRD4 (0.39) | BRD4LMNASMN1; SMN2HSD17B10NT5C2 | |
| SCHEMBL5857624 | 0.68 | BRD4 (0.71) | BRD4SMN1; SMN2NT5C2CYP3A4CREBBP | |
| SCHEMBL545883 | 0.66 | NPC1 (0.38) | BRD4SMN1; SMN2HSD17B10NT5C2NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143038-B1 | PEPTIDE-NUCLEIC ACID-MONOMERS AND -OLIGOMERS | UGISENSE AG (DE) | 2018-08-01 | — | — | EP | claimed |
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | UGISENSE AG (DE) | 2017-06-15 | — | — | US | claimed |
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | UGISENSE AG (DE) | 2017-06-15 | — | — | US | disclosed |
| US-7105648-B1 | Oligomers substituted by phosphite acid ester, phosphonic acid or carbaborane functions and the corresponding PNA monomers | UGICHEM GMBH (AU) | 2006-09-12 | — | — | US | disclosed |
| EP-1157031-B1 | OLIGOMERS SUBSTITUTED BY PHOSPHONIC ACID ESTER, PHOSPHONIC ACID OR CARBABORANE FUNCTIONS AND THE CORRESPONDING PNA MONOMERS | UGICHEM GMBH (AT) | 2003-12-17 | — | — | EP | disclosed |
| EP-1157031-A1 | OLIGOMERS SUBSTITUTED BY PHOSPHONIC ACID ESTER, PHOSPHONIC ACID OR CARBABORANE FUNCTIONS AND THE CORRESPONDING PNA MONOMERS | Ugichem GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000052038-A1 | OLIGOMERS SUBSTITUTED BY PHOSPHONIC ACID ESTER, PHOSPHONIC ACID OR CARBABORANE FUNCTIONS AND THE CORRESPONDING PNA MONOMERS | UGICHEM GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | DTYMK, POLM, PNKP | BRD4 4676/4885LMNA 770/4885SMN1; SMN2 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.